Abstract
Treatment for metastatic melanoma has not yet been established. Use of biological response modifiers (BRM) have been found to enhance therapeutic benefits. Rosenberg reported the effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and with tumor-infiltrating lymphocytes (TIL). We cultured patient's peripheral blood lymphocytes or TIL massively for a short time in the presence of recombinant interleukin 2 and immobilized anti-CD3 antibody. In clinical trials involving 10 cases, the mean number of harvested T cells after 14 days culture was 2.0×1010, and the mean expansion index was about 2000-fold. We called the acquired lymphocytes “immobilized anti-CD3 antibody-activated T lymphocytes (CD3-AT) ”and studied their clinical efficasy as a part of multidisciplinaly treatment. Of 10 malignant melanoma patients receiving CD3-AT, one had complete response and one had partial response. Moreover we administered CD3-AT to 2 patients of metastatic sweat gland carcinoma and one patient of progressive angiosarcoma, partial response of the angiosarcoma was observed. No side effects of CD3-AT have not yet been observed. Expanded T lymphocytes were infused to the patients with skin malignancies, and safety and feasibility was confirmed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
